| Angioedemas, Hereditary
Orladeyo vs Cinryze
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Orladeyo vs Cinryze with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCinryze has a higher rate of injection site reactions vs Orladeyo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cinryze but not Orladeyo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Orladeyo
Cinryze
At A Glance
Oral
Once daily
Plasma kallikrein inhibitor
IV infusion
Every 3-4 days
C1 esterase inhibitor (serpin)
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary (adults and pediatric patients >=12 years) 150 mg capsule orally once daily with food; reduce to 110 mg once daily with food for moderate or severe hepatic impairment (Child-Pugh Class B or C).
Angioedemas, Hereditary (pediatric patients 2 to <12 years) Weight-based oral pellets once daily with food: 72 mg (12 to <24 kg), 96 mg (24 to <32 kg), 108 mg (32 to <40 kg), or 132 mg (>=40 kg); avoid use in moderate or severe hepatic impairment.
Angioedemas, Hereditary (adults and adolescents 12 years and above) 1,000 IU IV every 3 or 4 days at 1 mL/min (10 min); for inadequate responders, doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered.
Angioedemas, Hereditary (pediatric patients 6-11 years) 500 IU IV every 3 or 4 days at 1 mL/min (5 min); dose may be adjusted up to 1,000 IU every 3 or 4 days based on individual response.
Contraindications
—
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to CINRYZE or any of its excipients
Adverse Reactions
Most common (>=10%) Abdominal pain, vomiting, diarrhea, back pain, gastroesophageal reflux disease
Serious QTc interval prolongation (at supratherapeutic doses), transaminase elevations
Postmarketing Nausea
Most common (>=5%) Headache, nausea, rash, vomiting, fever
Serious Cerebrovascular accident
Postmarketing Local infusion site reactions (inflammation or hematoma at infusion site), hypersensitivity
Pharmacology
Plasma kallikrein inhibitor; berotralstat binds to and inhibits plasma kallikrein's proteolytic activity, thereby reducing bradykinin generation and preventing angioedema attacks in patients with HAE due to C1-inhibitor deficiency or dysfunction.
C1 esterase inhibitor (serpin) that regulates complement and intrinsic coagulation (contact system) pathway activation; suppresses contact system activation by inactivating plasma kallikrein and factor XIIa, modulating vascular permeability by preventing bradykinin generation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Orladeyo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Cinryze
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Orladeyo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Cinryze
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Orladeyo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Cinryze
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OrladeyoView full Orladeyo profile
CinryzeView full Cinryze profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.